The company's platform uses sequencing and gene-regulatory data to identify the optimal combination of transcription factors or small molecules, enabling researchers to address the issues of efficacy, safety, and scalability associated with cell therapy development and manufacturing. Mogrify is applying its proprietary platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease. The company is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications.